IQVIA Holdings Inc. to acquire discovery services assets from Charles River Laboratories

IQVIA Holdings, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories.

The acquisition complements IQVIA Laboratories’ existing drug discovery capabilities to create a fully integrated, end-to-end drug discovery platform spanning target identification, hit-to-lead, lead optimization and early safety assessment. These expanded capabilities will broaden IQVIA’s ability to serve a wider range of drug modalities and therapeutic areas in early discovery research, including Oncology, Neurology, Immunology, Metabolism and Rare Diseases. Pharmaceutical and Biotech sponsors will benefit from the integration of IQVIA’s combined scientific, regulatory and clinical expertise from early-stage discovery research through to clinical development.

“This acquisition will meaningfully strengthen our ability to support clients earlier in the R&D lifecycle and complements our existing translational and clinical development capabilities,” said David Morris, president of IQVIA Laboratories. “Integrating these assets with our existing capabilities creates an industry-leading drug discovery platform with a track record of advancing discovery programs into clinical development.”